EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer

Matthew D Galsky, Sudeh Izadmehr, Menggang Yu, Samuel D Curtis iD, Christopher Douville, Maria Popoli, Janine Ptak, Lisa Dobbyn, Natalie Silliman, Kevin G Chan, Tanya B Dorff, Jeremy P Cetnar und 16 weitere

Proceedings of the National Academy of Sciences · 24.02.2026 · 123 (8)

DOI: 10.1073/pnas.2533449123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 18.02.2026. Verfasst von Matthew D Galsky und 27 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, DNA, Neoplasm, Biomarkers, Tumor, Circulating Tumor DNA. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Burroughs Wellcome Fund (BWF), NCI NIH HHS, Virginia and D.K. Ludwig Fund for Cancer Research (D.K. Ludwig Fund).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We previously reported initial results from a clinical trial testing a strategy in which patients with muscle-invasive bladder cancer (MIBC) achieving a clinical complete response after cystoscopic resection of the bladder tumor plus systemic therapy could forgo removal of their entire bladder (cystectomy). While the results were highly promising, a subset of patients omitting initial cystectomy developed recurrence highlighting the need for biomarkers to refine selection of patients for this approach. We here report long-term follow-up of these patients and investigate whether tumor DNA in the plasma (ctDNA) or urine (utDNA) could inform prognosis and the need for cystectomy. Three-year bladder-intact survival among patients with a complete clinical response following four rounds of systemic therapy was 69%. Metastatic risk was significantly higher for patients with detectable versus undetectable ctDNA presystemic therapy (HR 4.68; 95% CI 1.10-43.35; log-rank P = 0.036). Only 4.5% (1 of 22) of patients with undetectable baseline ctDNA developed metastatic disease. Undetectable ctDNA before or after systemic therapy was associated with extremely low metastatic risk. Urine utDNA was more sensitive than plasma ctDNA at detecting residual disease within the bladder, and detectable urine utDNA in patients with a complete clinical response was associated with shorter bladder-intact survival (HR 6.47, 95% CI 1.34-31.31; log-rank P = 0.008). These findings establish the conceptual and experimental foundation for incorporating ctDNA and utDNA assays into the management of patients with MIBC, particularly with respect to the need for cystectomy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsDNA, NeoplasmBiomarkers, TumorCirculating Tumor DNAHumansMaleFemaleCystectomyAgedPrognosisMiddle AgedUrinary BladderNeoplasm Invasiveness

Stichwörter der Autor:innen

biomarkerbladder cancerctDNAutDNA

Substanzen

DNA, NeoplasmBiomarkers, TumorCirculating Tumor DNA

Autor:innen und Institutionen

  • Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Department of Biostatistics, University of Michigan, Ann Arbor, MI 48109.
  • Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, MD 21287.
  • Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.
  • HHMI, Chevy Chase, MD 20815.

ORCID-Profile: Samuel D Curtis, Bert Vogelstein

Förderung

  • Burroughs Wellcome Fund (BWF)
  • NCI NIH HHS
  • Virginia and D.K. Ludwig Fund for Cancer Research (D.K. Ludwig Fund)
  • HHS | NIH (NIH)
  • NINDS NIH HHS
  • U.S. Department of Defense (DOD)
  • V Foundation for Cancer Research (VFCR)

Zitieren

APA

Galsky, M. D., Izadmehr, S., Yu, M., Curtis, S. D., Douville, C., Popoli, M., Ptak, J., Dobbyn, L., Silliman, N., Chan, K. G., Dorff, T. B., Cetnar, J. P., O'Neil, B., D'Souza, A., Mamtani, R., Kyriakopoulos, C. E., Brody, R., Sadimin, E., Mehrazin, R., …, & Wang, Y. (2026). Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer. Proceedings of the National Academy of Sciences, 123(8). https://doi.org/10.1073/pnas.2533449123

Vancouver

Galsky MD, Izadmehr S, Yu M, Curtis SD, Douville C, Popoli M, et al. Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer. Proceedings of the National Academy of Sciences. 2026;123(8). doi:10.1073/pnas.2533449123

BibTeX
@article{Galsky2026,
  author = {Galsky, Matthew D and Izadmehr, Sudeh and Yu, Menggang and Curtis, Samuel D and Douville, Christopher and Popoli, Maria and Ptak, Janine and Dobbyn, Lisa and Silliman, Natalie and Chan, Kevin G and Dorff, Tanya B and Cetnar, Jeremy P and O'Neil, Brock and D'Souza, Anishka and Mamtani, Ronac and Kyriakopoulos, Christos E and Brody, Rachel and Sadimin, Evita and Mehrazin, Reza and Chowell, Diego and Sfakianos, John and Daneshmand, Siamak and Pal, Sumanta K and Bettegowda, Chetan and Kinzler, Kenneth W and Papadopoulos, Nickolas and Vogelstein, Bert and Wang, Yuxuan},
  title = {Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {8},
  doi = {10.1073/pnas.2533449123}
}
Kostenlos starten →